Flores-Franco RA

Language: Spanish
References: 15
Page: 72-74
PDF size: 179.17 Kb.

REFERENCES

1. Secretaría de Salud (México). Documentos de consulta para el personal de salud. Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2020/08/No_uso_Tocilizumab.pdf.

2. Furlow B. CONVACTA trial raises questions about tocilizumab's benefit in COVID-19. Lancet Rheumatol. 2020;2(10):e592. https://doi.org/10.1016/s2665-9913(20)30313-1.

3. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020: ciaa954. https://doi.org/10.1093/cid/ciaa954.

4. Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. Rationale and evidence of the use of tocilizumab in COVID-19: a systemic review. Pulmonology. 2020;27(1):52-66. https://doi.org/10.1016/j.pulmoe.2020.07.003.

5. Moiseev S, Avdeev S, Tao E, Brovko M, Bulanov N, Zycova A, et al. Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study. Ann Rheum Dis Month. 2020; Oct 30. Online ahead of print. https://doi.org/10.1136/annrheumdis-2020-219265.

6. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2020;e206252. https://doi.org/10.1001/jamainternmed.2020.6252.

7. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicenter observational study. Lancet Rheumatol. 2020;2(10):e603-e612. https://doi.org/10.1016/s2665-9913(20)30277-0.

8. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. Preliminary report. N Engl J Med. 2020:NEJMoa2021436. https://doi.org/10.1056/nejmoa2021436.

9. Alessi J, de Oliveira GB, Schaan BD, Telo GH. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetol Metab Syndr. 2020;12:80. doi: 10.1186/s13098-020-00583-7.

10. Gianchandani R, Esfandiari NH, Ang L, Iyengar J, Knotts S, Choksi P, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69(10):2048-2053. https://doi.org/10.2337/dbi20-0022.

11. Rayman G, Lumb AN, Kennon B, Cottrell C, Nadi D, Page E, et al. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes. Diabetic Med. 2021;38(1):e14378. https://doi.org/10.1111/dme.14378.

12. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42. https://doi.org/10.1016/j.cytogfr.2020.04.002.

13. Almeida-Monteiro RA, de Oliveira EP, Nascimento-Saldiva PH, Dolhnikoff M, Duarte-Neto AN, BIAS-Brazilian Image Autopsy Study Group. Histological-ultrasonographical correlation of pulmonary involvement in severe COVID-19. Intensive Care Med. 2020;46(9):1766-1768. https://doi.org/10.1007/s00134-020-06125-z.

14. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128-136.e4. https://doi.org/10.1016/j.jaci.2020.05.008.

15. López-Jiménez F, Obrador-Vera GT, Lamas GA. Manual de medicina basada en la evidencia. México: El Manual Moderno; 2001.